Nektar Therapeutics said a Phase 2b study for its lead immunology drug failed in severe alopecia, but executives blamed the miss on trial enrollment errors

Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies. The startup

Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide,

Hey, it’s Shelby. I’m back from maternity leave, during which I surprised myself by embracing health tech more than ever before. I’m admittedly a technology

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.